PSIL 📈 AdvisorShares Psychedelics - Overview
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US00768Y3624 • Miscellaneous Sector
PSIL: Psychedelic, Medicine, Research, Life Sciences, Biotech, Pharmaceuticals, Derivatives
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.
Additional Sources for PSIL ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PSIL ETF Overview
| Market Cap in USD | 7m |
| Category | Miscellaneous Sector |
| TER | 0.99% |
| IPO / Inception | 2021-09-15 |
PSIL ETF Ratings
| Growth 5y | -84.5% |
| Fundamental | - |
| Dividend | 37.2% |
| Rel. Strength Industry | -137 |
| Analysts | - |
| Fair Price Momentum | 8.73 USD |
| Fair Price DCF | - |
PSIL Dividends
| Dividend Yield 12m | 1.29% |
| Yield on Cost 5y | 0.17% |
| Annual Growth 5y | 44.82% |
| Payout Consistency | 51.3% |
PSIL Growth Ratios
| Growth Correlation 3m | -37.7% |
| Growth Correlation 12m | -54.7% |
| Growth Correlation 5y | -97.2% |
| CAGR 5y | -45.52% |
| CAGR/Mean DD 5y | -0.61 |
| Sharpe Ratio 12m | 0.22 |
| Alpha | -29.87 |
| Beta | 0.78 |
| Volatility | 68.30% |
| Current Volume | 5.9k |
| Average Volume 20d | 11.3k |
What is the price of PSIL stocks?
As of January 15, 2025, the stock is trading at USD 12.70 with a total of 5,882 shares traded.
Over the past week, the price has changed by -0.23%, over one month by +20.52%, over three months by +64.67% and over the past year by -8.99%.
As of January 15, 2025, the stock is trading at USD 12.70 with a total of 5,882 shares traded.
Over the past week, the price has changed by -0.23%, over one month by +20.52%, over three months by +64.67% and over the past year by -8.99%.
Is AdvisorShares Psychedelics a good stock to buy?
No, based on ValueRay Analyses, AdvisorShares Psychedelics (NYSE ARCA:PSIL) is currently (January 2025) a stock to sell. It has a ValueRay Growth Rating of -84.53 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PSIL as of January 2025 is 8.73. This means that PSIL is currently overvalued and has a potential downside of -31.26%.
No, based on ValueRay Analyses, AdvisorShares Psychedelics (NYSE ARCA:PSIL) is currently (January 2025) a stock to sell. It has a ValueRay Growth Rating of -84.53 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PSIL as of January 2025 is 8.73. This means that PSIL is currently overvalued and has a potential downside of -31.26%.
Is PSIL a buy, sell or hold?
AdvisorShares Psychedelics has no consensus analysts rating.
AdvisorShares Psychedelics has no consensus analysts rating.
What are the forecast for PSIL stock price target?
According to ValueRays Forecast Model, PSIL AdvisorShares Psychedelics will be worth about 9.6 in January 2026. The stock is currently trading at 12.70. This means that the stock has a potential downside of -24.09%.
According to ValueRays Forecast Model, PSIL AdvisorShares Psychedelics will be worth about 9.6 in January 2026. The stock is currently trading at 12.70. This means that the stock has a potential downside of -24.09%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 9.6 | -24.1% |